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Zadnjih nekoliko desetlje}a svjedoci smo konstantno rastu}eg problema an-
timikrobne rezistencije zbog kojeg je Vije}e Europske Unije donijelo rezoluciju
te preporuke o razumnoj uporabi antibiotika u humanoj medicini. Naglasak u
preporukama je stavljen na uspostavljanje mre`e pra}enja antimikrobne rezis-
tencije te implementiranje mjera za doprinos razumnoj potro{nji antibiotika
kroz razvijanje nacionalnih smjernica o upotrebi antibiotika. Uspostava inter-
disciplinarnog nacionalnog tijela (ICM, od engl. interdisciplinary coordinating
mechanism) za koordiniranje svih aktivnosti na podru~ju rezistencije bakterija
na antibiotike predlo`ena je kao glavni instrument implementacije preporuka.
Kao ICM u Nizozemskoj je osnovana Radna grupa za antimikrobnu strategiju
(SWAB), a u Hrvatskoj Interdisciplinarna sekcija za kontrolu rezistencije na an-
tibiotike (ISKRA). Dobra suradnja izme|u SWAB-a i ISKRA-e zapo~eta je
kroz Matra (Matra Pre-Accession Programme, MPAP) projekt "Pra}enje an-
timikrobne rezistencije u humanoj medicini" nizozemskog Ministarstva vanj-
skih poslova. Nizozemska je zemlja s najni`om potro{njom antibiotika u Europi
te niskim udjelom antibiotske rezistencije kod ve}ine bakterija. Rezistencija na
neke antibiotike, ipak, raste.
Management of the antibiotic resistance problem – approach of the Dutch
Working Party on Antibiotic Policy
Professional paper
In the past decades we are witnessing an increasing antibiotic resistance prob-
lem to which the EU Ministers of Health responded by issuing a "Council
Recommendation on the prudent use of antimicrobial agents in human medi-
cine" with the recommendation of establishing antimicrobial resistance surveil-
lance systems and implementing measures to support the prudent use of antibi-
otics by setting evidence based guidelines. Intersectoral Coordinating
Mechanisms (ICM) at national levels have been suggested as instruments of im-
plementation. Consequently the Working Party on Antibiotic Policy (SWAB)
was founded in the Netherlands, and the Interdisciplinary Section for Antibiotic
Resistance Control (ISKRA) in Croatia. Good colaboration between the SWAB
and the ISKRA started through the Matra Pre-Accession Programme (MPAP)
project "Antimicrobial resistance surveillance in human medicine" of the Dutch
Ministry of Foreign Affairs. The Netherlands is the country with the lowest an-
tibiotic consumption in Europe and with low antibiotic resistance rates in the
majority of pathogens. However, resistance to some antibiotics is rising.
Introduction
In the past decades we are witnessing an increasing re-
sistance problem in the field of public health, in general
practice and in hospitals. To name a few examples of high
impact, multiple resistance in Neisseria gonorrhoea,
Mycobacterium tuberculosis, Staphylococcus aureus,
Escherichia coli and Klebsiella pneumoniae are an impor-
tant threat for our ability to treat serious infections.
Following a conference on the recommendation of the EU
Ministers of Health and on the initiative of the Danish
Ministry of Health and the Ministry of Food, Agriculture
and Fisheries, the Council of the European Union issued a
"Council Recommendation on the prudent use of antimi-
crobial agents in human medicine" [1]. This action must be
considered a milestone in the European commitment to
fight antimicrobial resistance. In the Council Recom-
mendations an EU resolution from 1999 is quoted, which
states that antimicrobial resistance increases morbidity
and mortality due to communicable disease and leads not
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Mechanisms (ICM) based on the EU recommendations [1]
and have similar tasks. Apart from the representatives of
the societies for clinical microbiology, infectious diseases
and clinical pharmacology ISKRA includes representa-
tives of a wider range of interested parties like representa-
tives of the Ministry for Agriculture, Fisheries and Rural
Development and the Ministry of Science, Education and
Sports as well as the representative of the National
Infection Control Committee. When constituting the
Croatian ICM the Croatian Ministry of Health and Social
Welfare took the advantage of collaboration with the
Dutch Ministry of Foreign Affairs through the MATRA
Pre-Accession Programme (MPAP) project "Anti-
microbial resistance surveillance in human medicine". The
name of the Matra Programme derives from the Dutch for
social transformation, "maatschappelijke transformatie".
The beneficiary of the project was the Croatian Reference
Center for Antibiotic Resistance Surveillance and from the
Dutch side project partners were the Dutch Ministry of
Health, Welfare and Sports, the SWAB, the RIVM and the
Working Party for Infection Prevention (WIP). As the
SWAB is oriented towards international collaboration the
members of SWAB gladly took part in the MATRAproject
mostly contributing to the area of guidelines development
and implementation. In a number of visits to Croatia the
Dutch clinical microbiology and infectious disease doc-
tors took part in workshops on guideline development. At
the first workshop the methodology of guideline writing
was discussed and the two most important topics for pri-
mary health care (sore throat and urinary tract infections)
and the two most important hospital topics (MRSA control
and surgical prophylaxis) were selected. After the working
groups for each topic were set up by the Croatian Ministry
of Health the SWAB members were involved in draft
guideline analysis and implementation policy. A good col-
laboration between the SWAB and the ISKRA continued
after the ending of the MATRA project. 
Antimicrobial drug use in the Netherlands
Surveillance of antimicrobial use consists of two parts:
primary health care antimicrobial use and antibiotic use in
hospitals. The Foundation for Pharmaceutical Statistics
(SFK) is in charge for collecting and analysing primary
health care antibiotic consumption data and SWAB is col-
lecting and analyzing hospital antimicrobial consumption
data obtained from hospital pharmacists. Data on antibiot-
ic use are expressed in defined daily doses (DDD) per hun-
dred patient days and per hundred admissions, because
trends over time in both units of measurement do not al-
ways correlate. These data are published in NethMap.
Over the past decade, outpatient consumption of antibi-
otics has risen only slightly, from 9.9 to 11.1 DDD/1,000
inhabitants/day in 2008 [2]. However, the use of antibi-
otics is still low if compared with other European countries
[2, 3]. In the primary health care consumption of co-amox-
iclav gradually replaced amoxicillin and the use of
quinolones increased. Nitrofurantoin use increased while
only to a diminution of quality of life but also to additional
health and medical care costs, and that action needs to be
taken at community level.
In the aim to contain the increase of resistance it is rec-
ommended to establish antimicrobial resistance surveil-
lance systems, to implement measures to support the pru-
dent use of antibiotics by setting evidence based guide-
lines, to promote and design educational activities for
health providers and to make relevant data available to the
public. In order to create instruments for the implementa-
tion of the EU recommendations, Intersectoral Coord-
ination Mechanisms at national level have been suggested.
Approach of the Dutch Working Party on
Antibiotic Policy (SWAB)
In the Netherlands a multidisciplinary Working Party
on Antibiotic Policy (Stichting Werkgroep Antibiotica
Beleid, SWAB) was founded in 1996, as an initiative of the
Society for Infectious Diseases, the Dutch Society for
Medical Microbiology and the Dutch Association of
Hospital Pharmacists. In the board of SWAB, in addition to
members of the societies above-mentioned, a veterinarian,
a general practitioner and a paediatrician are represented.
Presently the SWAB is the ECDC (ECDC – European
Centre for Disease Prevention and Control) National
Antimicrobial Resistance Focal Point. SWAB strives after
the aims as recommended by the EU Commission by opti-
mizing the use of antimicrobial agents through guideline
development, education and surveillance of resistance and
antibiotic use. Following advice by the Dutch Advisory
Council on Health Research in 2000 on the containment of
resistance, in 2001 SWAB was appointed by the Dutch
Ministry of Health, Welfare and Sports to coordinate the
surveillance of resistance in collaboration with the
National Institute for Public Health and the Environment
(Rijksinstituut voor Volksgezondheid en Milieu, RIVM),
currently with the Center for Infectious Disease Control
(CiB) in the same institute. The surveillance of the use of
antibiotics and the development of antibiotic guidelines is
funded structurally by the CiB.
Because of the emerging resistance against medically
relevant antibiotics in the veterinary field in a departmen-
tal platform between the Ministry of Agriculture, Nature
and Food Quality and the Ministry of Health, Welfare and
Sport experts discuss with the politicians the actions to be
undertaken. Counterpart of the SWAB in this platform is
the Veterinary Antibiotic Resistance Surveillance Working
group (VANTURES).
The SWAB, the ISKRA and the MATRA
project
SWAB is comparable to the Interdisciplinary Section
for Antibiotic Resistance Control (ISKRA) of the Croatian
Ministry of Health and Social Welfare. Both organizations
were founded as national Intersectoral Coordination
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trimethoprim use decreased which is in accordance with
the revised guidelines for the treatment of cystitis.
Tetracyclines (mainly doxycycline) represented 25 % of
total antibiotic use in primary health care. Distribution of
the use of antibiotics for systemic use in primary health
care in 2008 is shown in Figure 1.
In hospitals the overall antibiotic use increased signifi-
cantly from 47.8 to 61 DDD per 100 patient days in 2007,
but this increase was due to the steady reduction in the av-
erage length of patient hospital stays while an increase of
around 20 % in the number of admissions was seen over
the past five years evidently leading to more medical inter-
ventions and more antibiotic use in hospitals in general.
Overall antibiotic use per 100 admitted patients has re-
mained partically the same, 336.2 DDD/100 admissions in
2003 and 335.0 DDD/100 admissions in 2007. Exceptions
are the use of quinolones and glycopeptides. The con-
sumption of ciprofloxacin in 2007 has significantly in-
Figure 1.Distribution of antibiotic consumption for systemic use in primary health care in the Netherlands, 2008, adapted from data pub-
lished on NethMap [2]
Slika 1. Raspodjela potro{nje antibiotika za sistemnu uporabu u primarnoj zdravstvenoj za{titi u Nizozemskoj, 2008., izra|eno prema
podacima objavljenima na NethMap [2]
Figure 2.Distribution of hospital consumption of antibiotics for systemic use in The Netherlands, 2007, adapted from data published on
NethMap [4]
Slika 2. Raspodjela bolni~ke potro{nje antibiotika za sistemsku uporabu u Nizozemskoj, 2007., izra|eno prema podacima objavljeni-
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creased since 1999 (2.5 to 5.5 DDD/100 patient days, 20 to
35 DDD/100 admissions) and this may be explained by an
increase in the incidence of gram-negative resistant micro-
organisms. Vancomycin use has also increased (0.35 to 0.7
DDD/100 patient-days, 2.3 to 4.8 DDD/100 admissions)
[2]. This might be due either to an increased focus on
staphylococcal infections or an increased incidence of se-
rious staphylococcal infections in the community and in
health care settings. Distribution of the use of antibiotics
for systemic use in 2007 is shown in Figure 2. 
Resistance Surveillance in the Netherlands
Similary to the surveillance of antimicrobial usage, an-
tibiotic resistance surveillance in the Netherlands is divid-
ed in two branches: primary health care and hospital resis-
tance surveillance.
Primary health care surveillance is based on several
studies ongoing in various parts of the Netherlands, coor-
dinated by the national project Surveillance of Extramural
Resistance in the Netherlands (SERIN). Ongoing surveil-
lance systems on resistance rates in primary health care in-
clude:
– Resistance data for Staphylococcus aureus as part of
the indigenous flora of healthy persons as to deter-
mine the basic level of resistance in the human reser-
voir
– Resistance rate of indicator organisms (S. aureus and
Escherichia coli) in patients visiting their general
practitioner
– Carrier state and level of resistance of Streptococcus
pneumoniae in healthy children and healthy adults
– In 2006 the RIVM started a surveillance of resistance
of Neisseria gonorrhoeae among patients from out-
patient – sexually transmited infections (STI) clinics
(the GRAS project)
– Since 1993 the Netherlands Reference Laboratory
for Bacterial Meningitis has been determining the re-
sistance level of Neisseria meningitidis from pa-
tients admitted to hospital for meningococcal disease
– The first isolate of Mycobacterium tuberculosis of
each patient with tuberculosis in the Netherlands is
routinely sent to the RIVM for susceptibility testing
and confirmation of identification.
The overall prevalence of antibiotic resistance in hos-
pitals is estimated by using resistance data generated in
routine clinical care. These data are divided in two major
Figure 3.Resistance trends of E. coli to amoxicillin, trimethoprim, ceftazidime, aminoglycosides and ciprofloxacin in unselected hospi-
tal departments, Intensive Care Units and Urology Services in The Netherlands. NethMap 2008 [2]
Slika 3. Trendovi u rezistenciji E. coli na amoksicilin, trimetoprim, ceftazidim, aminoglikozide i ciprofloksacin na bolni~kim odjelima,
u jedinicama intenzivne njege i na urolo{kim odjelima u Nizozemskoj. NethMap 2008. [2]
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categories: unselected and selected hospital departments
data. Unselected hospital departments and outpatient clin-
ics data are collected from local laboratories by RIVM.
Strains from selected hospital departments are collected
by the Laboratory of Medical Microbiology of Maastricht
University. These activities are covered by the national
project for Surveillance of Intramural Resistance in the
Netherlands (SIRIN). The population coverage for the
hospital resistance surveillance is approximately 30 %.
In outpatient setting the resistance rates in E. coli are
>30 % for amoxicillin and >20 % for co-trimoxazole
whereas resistance to other antibiotics is low. In intensive
care units co-amoxiclav resistance rate in E. coli in 2007
was 25 % with most strains showing MIC of intermediate
category. These strains were not found among the commu-
nity isolates. Ceftazidime-resistance level in the intensive
care units and urology services was less than 1 % and
showed no increase. Ciprofloxacin-resistance increased
steadily among E. coli from unselected hospital depart-
ments, slowly during the first six years from 1–3 %, then
more rapidly during the next six years: from 3 % in 2001 to
9 % in 2007, (Figure 3). This trend was also observed in the
intensive care units. Co-amoxiclav-resistance in K. pneu-
moniae in intensive care units fluctuated at a high level
(4–19 %) and resistance to cefotaxime and ceftazidime
was sporadic. Ceftazidime and carbapenem resistance
among P. aeruginosa isolated in intensive care units re-
mained below 2 % [4]. Yearly a small number of MRSA
were isolated from the intensive care units (N = 24 from
1996–2006) in the SWAB surveillance network. However,
the incidence of MRSA increased 42 % since 2006 mostly
due to the rise of the new non-typeable NT-MRSA [3],
(Figure 4). The rate of penicillin non-susceptible pneumo-
cocci (PNS) is 2 % and macrolide resistance is 10 %.
Resistance in the Netherlands compared to
other EU countries
The Netherlands together with Norway and Sweden
are representing the countries with very low MRSA rates
(<1 %). The proportion of invasive isolates of E. coli with
resistance to third generation cephalosporins is still low
and was reported less than 5 %. However, the resistance to
fluoroquinolones follows the same trend as in the other
parts of Europe and has been increasing throughout the
years, with the current resistance of 10–25 %. The
Netherlands is one of very few countries with low inci-
dence of invasive K. pneumoniae isolates resistant to the
3rd generation cephalosporins (5–10 %). The proportion of
P. aeruginosa invasive isolates resistant to ceftazidime,
fluoroquinolones or carbapenems is 5–10 % which is low
compared to other European countries [5].
Surveillance in the veterinary field
Therapeutic usage of antibiotics in food animals
steadily increases, and it is followed by simultaneous in-
crease of resistance levels in animal bacteria [6]. This fact
and its direct influence on humans made surveillance of
antibiotic resistance in animal bacteria and antibiotic us-
age in animals as imperative. In the Netherlands the Royal
Veterinary Association's Antibiotic Policy Working Party
published its policy in 1994 [6]. Rational and restrictive
use of antibiotics was one of the foundations of this policy.
Guidelines for therapy called "formularia" have been de-
veloped and their use promoted since the mid nineties of
the last century. The data on monitoring of antimicrobial
resistance and antibiotic usage in animals in the
Netherlands is published every year in MARAN
Figure 4.Distribution of MRSA isolates in the Netherlands. Nethmap 2008 [2]











































soprek_2.qxd  17.3.2010  11:44  Page 155
156
S. [OPREK i sur. Pristup problemu antimikrobne rezistencije – iskustvo nizozemske Radne grupe ...
Infektolo{ki glasnik 29:4, 151–156 (2009) 
(Monitoring of Antimicrobial Resistance and Antibiotic
Usage in Animals in the Netherlands) by VANTURES.
The information presented in MARAN is based on a colla-
tion of data from ongoing surveillance systems on the use
of antimicrobial agents in animal husbandry and the devel-
opment of antimicrobial resistance in bacteria of animal
origin and of relevance to public health. This study was
primarily financed by the Ministry of Agriculture, Nature
and Food Quality, through project 'Antimicrobial
Resistance Research in Animals'. As an ICM, SWAB is in
tight connection with VANTURES.
Antibiotic policy, therapeutic guidelines
Guideline programmes have a long tradition among the
Dutch. It was started in the late 1980s by the Dutch College
for General Practitioners, and was continued by SWAB.
Since its conception, the SWAB has developed nation-
al guidelines for the use of antibiotics. Guidelines are pub-
lished in a Dutch medical journal (Nederlands Tijdschrift
voor Geneeskunde) and in English on the SWAB website
www.swab.nl. First guidelines aimed only at the hospital-
ized adult patients. They were based on the AGREE
methodology (Appraisal of Guidelines, Research and
Evaluation) [7, 8]. In 2006 SWAB introduced the electron-
ic national antibiotic guide "SWAB-ID" for the antibiotic
treatment and prophylaxis of common infectious diseases
in hospitals. This guide also contains information on the
most important characteristics of antimicrobial drugs.
Advice on antibiotic treatment is based on existing evi-
dence- based guidelines, where available. Where no guide-
line is available, the advice is based on an inventory of the
antibiotic policies of the 12 Dutch centers with an infec-
tious disease or medical microbiology training pro-
gramme.
Disscusion
Increasing antibiotic resistance is a European and a
world wide problem that is addressed by the various
European professional societies and the EU Ministers of
Health. Both the Netherlands and Croatia have good an-
tibiotic resistance and antibiotic consumption surveillance
systems in place and both countries are taking part in the
European surveillance projects, the EARSS (EARSS-
European Antimicrobial Resistance Surveillance System)
and the ESAC (ESAC-European Surveillance of Anti-
microbial Consumption). Consumption of antibiotics in
the Netherlands is low as compared with other European
countries and resistance rates are low for the majority of
pathogens. However, some trends in community acquired
pathogens like high amoxicillin and co-trimoxazole and
increasing quinolone resistance in E. coli seem to be simi-
lar in the Netherlands as in other European countries.
Analysis of antibiotic consumption surveillance data show
that some changes in antibiotic consumption of different
antibiotic classes can be explained by the change in guide-
lines on antibiotic use. The Netherlands has a long tradi-
tion in guideline writing [9] and this may be the clue to the
rational antibiotic prescribing habits among the Dutch
doctors. However, the control of guideline adherence is
one of the weak points of antibiotic policy in general.
Antibiotic treatment in hospitalized patients with a variety
of underlying conditions and in the era of resistant
pathogens is a very challenging task and should be guided
by a team of infectious diseases and clinical microbiology
professionals. Antibiotic prescribing auditing is an impor-
tant tool in estimating a degree of compliance to antibiotic
guidelines. One of the new actions to be taken by SWAB is
to start a nation wide project on antibiotic prescribing au-
diting in order to study the adherence to SWAB guidelines.
The SWAB is always open for the international collabora-
tion and is looking forward to the future collaboration with
the Croatian ISKRA as these two ICMs have similar tasks
and goals.
References
[1] Council of the European Union. Council Recommendation of 15
November 2001 on the prudent use of antimicrobial agents in hu-
man medicine. Official Journal of the European Union 2002 Feb.
L 34/13.
[2] Consumption of antimicrobial agents and antimicrobial resistance
among medically important bacteria in the Netherlands, NethMap
2009. Available from URL: http://www.swab.nl. Accessed on 15
December 2009.
[3] Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient
antibiotic use in Europe and association with resistance: a cross-
national database study. Lancet 2005; 365: 579–87.
[4] Consumption of antimicrobial agents and antimicrobial resistance
among medically important bacteria in the Netherlands, NethMap
2008. Available from URL: http://www.swab.nl. Accessed on 15
December 2009.
[5] European Antimicrobial Resistance Surveillance System, EARSS
Annual Report 2008. RIVM, Bilthoven, the Netherlands 2009.
Available from URL: www.rivm.nl/earss/. Accessed on 15
December 2009.
[6] MARAN 2007. Monitoring of antimicrobial Resistance and
Antibiotic Usage in Animals in the Netherlands in 2006/2007.
VANTURES, Lelystad, the Netherlands 2007.
[7] MacDermid JC, Brooks D, Solway S, Switzer-McIntyre S,
Brosseau L, Graham ID. Reliability and validity of the AGREE in-
strument used by physical therapists in assessment of clinical prac-
tice guidelines. BMC Health Services Research 2005; 5:1–12.
[8] Prins JM, Kullberg BJ, Gyssens IC. National guidelines for the use
of antibiotics in hospitalized adult patients: the SWAB guidelines
revisited. Neth J Med 2005;63:288–290.
[9] Prins JM, Degener JE, De Neeling AJ, I C Gyssens, the SWAB
board. Experiences with the Dutch Working Party on Antibiotic
Policy (SWAB) Euro Surveill 2008;13:1–4 Available from URL:
www.eurosurveillance.org. Accessed on 15 December 2009.
soprek_2.qxd  17.3.2010  11:44  Page 156
